Structural analysis of botulinum neurotoxin serotype F light chain: Implications on substrate binding and inhibitor design

被引:54
作者
Agarwal, R
Binz, T
Swaminathan, S [1 ]
机构
[1] Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA
[2] Hannover Med Sch, Dept Biochem, D-30623 Hannover, Germany
关键词
D O I
10.1021/bi0510072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The seven serologically distinct Clostridium botulinum neurotoxins (BoNTs A-G) are zinc endopeptidases which block the neurotransmitter release by cleaving one of the three proteins of the soluble N-ethylmaleimide-sensitive-factor attachment protein receptor complex (SNARE complex) essential for the fusion of vesicles containing neurotransmitters with target membranes. These metallopeptidases exhibit unique specificity for the substrates and peptide bonds they cleave. Development of countermeasures and therapeutics for BoNTs is a priority because of their extreme toxicity and potential misuse as biowarfare agents. Though they share sequence homology and structural similarity, the structural information on each one of them is required to understand the mechanism of action of all of them because of their specificity. Unraveling the mechanism will help in the ultimate goal of developing inhibitors as antibotulinum drugs for the toxins. Here, we report the high-resolution structure of active BoNT/F catalytic domain in two crystal forms. The structure was exploited for modeling the substrate binding and identifying the S1' subsite and the putative exosites which are different from BoNT/A or BoNT/B. The orientation of docking of the substrate at the active site is consistent with the experimental BoNT/A-LC:SNAP-25 peptide model and our proposed model for BoNT/E-LC:SNAP-25.
引用
收藏
页码:11758 / 11765
页数:8
相关论文
共 42 条
  • [1] Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme
    Agarwal, R
    Binz, T
    Swaminathan, S
    [J]. BIOCHEMISTRY, 2005, 44 (23) : 8291 - 8302
  • [2] Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212→Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway
    Agarwal, R
    Eswaramoorthy, S
    Kumaran, D
    Binz, T
    Swaminathan, S
    [J]. BIOCHEMISTRY, 2004, 43 (21) : 6637 - 6644
  • [3] Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain
    Agarwal, R
    Eswaramoorthy, S
    Kumaran, D
    Dunn, JJ
    Swaminathan, S
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2004, 34 (01) : 95 - 102
  • [4] Enzymatic autocatalysis of botulinum a neurotoxin light chain
    Ahmed, SA
    Byrne, MP
    Jensen, M
    Hines, HB
    Brueggemann, E
    Smith, LA
    [J]. JOURNAL OF PROTEIN CHEMISTRY, 2001, 20 (03): : 221 - 231
  • [5] Light chain of botulinum a neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active
    Ahmed, SA
    Smith, LA
    [J]. JOURNAL OF PROTEIN CHEMISTRY, 2000, 19 (06): : 475 - 487
  • [6] Bennett Mark K., 1994, Current Opinion in Neurobiology, V4, P324, DOI 10.1016/0959-4388(94)90092-2
  • [7] NUCLEOTIDE-SEQUENCE OF THE GENE ENCODING CLOSTRIDIUM-BOTULINUM NEUROTOXIN TYPE-D
    BINZ, T
    KURAZONO, H
    POPOFF, MR
    EKLUND, MW
    SAKAGUCHI, G
    KOZAKI, S
    KRIEGLSTEIN, K
    HENSCHEN, A
    GILL, DM
    NIEMANN, H
    [J]. NUCLEIC ACIDS RESEARCH, 1990, 18 (18) : 5556 - 5556
  • [8] Arg362 and Tyr365 of the botulinum neurotoxin type a light chain are involved in transition state stabilization
    Binz, T
    Bade, S
    Rummel, A
    Kollewe, A
    Alves, J
    [J]. BIOCHEMISTRY, 2002, 41 (06) : 1717 - 1723
  • [9] Substrate recognition strategy for botulinum neurotoxin serotype A
    Breidenbach, MA
    Brunger, AT
    [J]. NATURE, 2004, 432 (7019) : 925 - 929
  • [10] Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254